RU2263109C2 - ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО - Google Patents

ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО Download PDF

Info

Publication number
RU2263109C2
RU2263109C2 RU2001133360/04A RU2001133360A RU2263109C2 RU 2263109 C2 RU2263109 C2 RU 2263109C2 RU 2001133360/04 A RU2001133360/04 A RU 2001133360/04A RU 2001133360 A RU2001133360 A RU 2001133360A RU 2263109 C2 RU2263109 C2 RU 2263109C2
Authority
RU
Russia
Prior art keywords
amino
dihydro
oxo
carbonyl
alkyl
Prior art date
Application number
RU2001133360/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2001133360A (ru
Inventor
Рональд Дж. БАЙДИДЖЕР (US)
Рональд Дж. БАЙДИДЖЕР
Ченгд ВУ (CN)
Ченгд ВУ
Джамал М. КАССИР (LB)
Джамал М. КАССИР
Уен ЛИ (CN)
Уен ЛИ
Роберт В. МАРКЕТ (US)
Роберт В. МАРКЕТ
Иан Л. Скотт (GB)
Иан Л. СКОТТ
Джордж У. ХОЛЛЭНД (US)
Джордж У. ХОЛЛЭНД
Кай ЧЕН (CN)
Кай ЧЕН
Original Assignee
Тексэс Байотекнолоджи Копэрейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тексэс Байотекнолоджи Копэрейшн filed Critical Тексэс Байотекнолоджи Копэрейшн
Publication of RU2001133360A publication Critical patent/RU2001133360A/ru
Application granted granted Critical
Publication of RU2263109C2 publication Critical patent/RU2263109C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2001133360/04A 1999-05-07 2000-05-05 ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО RU2263109C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13297199P 1999-05-07 1999-05-07
US60/132,971 1999-05-07

Publications (2)

Publication Number Publication Date
RU2001133360A RU2001133360A (ru) 2003-07-20
RU2263109C2 true RU2263109C2 (ru) 2005-10-27

Family

ID=22456441

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001133360/04A RU2263109C2 (ru) 1999-05-07 2000-05-05 ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО

Country Status (23)

Country Link
EP (1) EP1176956B1 (https=)
JP (1) JP5132855B2 (https=)
AT (1) ATE383153T1 (https=)
AU (1) AU5267900A (https=)
CA (1) CA2373360C (https=)
CY (1) CY1107438T1 (https=)
CZ (1) CZ303312B6 (https=)
DE (1) DE60037726T2 (https=)
DK (1) DK1176956T3 (https=)
ES (1) ES2296625T3 (https=)
IL (2) IL146311A0 (https=)
IN (1) IN2001KN01110A (https=)
MX (1) MXPA01011340A (https=)
NO (1) NO324421B1 (https=)
NZ (1) NZ515248A (https=)
PL (1) PL205322B1 (https=)
RO (1) RO122246B1 (https=)
RU (1) RU2263109C2 (https=)
SI (1) SI20744B (https=)
SK (1) SK286696B6 (https=)
TR (2) TR200103178T2 (https=)
WO (1) WO2000067746A1 (https=)
ZA (1) ZA200108774B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632885C2 (ru) * 2012-01-31 2017-10-11 Дайити Санкио Компани, Лимитед Производные пиридона
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
RS52392B (sr) * 2002-02-14 2013-02-28 Pharmacia Corporation Supstituisani piridinoni kao modulatori p38 map kinaze
PE20040728A1 (es) 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
JP2005535710A (ja) 2002-08-09 2005-11-24 トランス テック ファーマ,インコーポレイテッド アリールおよびヘテロアリール化合物ならびに凝固を調節する方法
WO2004044046A2 (en) * 2002-11-08 2004-05-27 Encysive Pharmaceuticals Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
TW200500343A (en) 2002-12-20 2005-01-01 Vertex Pharma Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
EP1917244A2 (de) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
CA2680366C (en) * 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
WO2009015485A1 (en) 2007-08-01 2009-02-05 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
AU2010241742A1 (en) * 2009-04-27 2011-11-17 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
WO2012033548A2 (en) * 2010-09-07 2012-03-15 E. I. Du Pont De Nemours And Company Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles
CN102596933B (zh) 2009-09-09 2014-09-17 杜邦公司 除草剂嘧啶酮衍生物
CN105745206B (zh) 2013-09-20 2019-08-13 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
US20170002077A1 (en) 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) * 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
MX2019012699A (es) 2017-04-28 2020-12-11 Texas Childrens Hospital Nanoparticulas dirigidas.
TWI834634B (zh) * 2018-02-02 2024-03-11 美商建南德克公司 醫藥化合物、其鹽類、其製劑及其等之製備和使用之方法
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484946A (en) * 1994-12-05 1996-01-16 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine β-alanine urea analogs
US5721366A (en) * 1993-03-31 1998-02-24 G. D. Searle & Co Platelet aggregation inhibitors
RU2106340C1 (ru) * 1993-06-30 1998-03-10 Санкио Компани Лимитед Амидо- или карбамидо- производные, или их фармацевтические соли и композиция, обладающая ингибирующей активностью в отношении ацил-соа:холестерин ацилтрансферазы

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614189A1 (de) * 1976-04-02 1977-10-20 Hoechst Ag Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JPH07304755A (ja) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
ES2166996T3 (es) * 1996-05-15 2002-05-01 Searle & Co Metodo y reactivo para controlar los niveles en sangre de compuestos antiplaquetarios.
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
US6630488B1 (en) * 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721366A (en) * 1993-03-31 1998-02-24 G. D. Searle & Co Platelet aggregation inhibitors
RU2106340C1 (ru) * 1993-06-30 1998-03-10 Санкио Компани Лимитед Амидо- или карбамидо- производные, или их фармацевтические соли и композиция, обладающая ингибирующей активностью в отношении ацил-соа:холестерин ацилтрансферазы
US5484946A (en) * 1994-12-05 1996-01-16 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine β-alanine urea analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALTERS, ET AL, J. Med. Chem., 1994, v.37, p.2527-2536. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632885C2 (ru) * 2012-01-31 2017-10-11 Дайити Санкио Компани, Лимитед Производные пиридона
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones

Also Published As

Publication number Publication date
PL351396A1 (en) 2003-04-07
DE60037726D1 (de) 2008-02-21
SI20744A (sl) 2002-06-30
TR200103178T2 (tr) 2002-05-21
CZ20013963A3 (cs) 2002-04-17
MXPA01011340A (es) 2003-08-01
CZ303312B6 (cs) 2012-07-25
SK286696B6 (sk) 2009-03-05
ATE383153T1 (de) 2008-01-15
IL146311A (en) 2011-10-31
WO2000067746A8 (en) 2002-02-28
JP5132855B2 (ja) 2013-01-30
CA2373360C (en) 2011-09-06
CY1107438T1 (el) 2012-12-19
NO20015418D0 (no) 2001-11-06
PL205322B1 (pl) 2010-04-30
NO20015418L (no) 2001-12-21
NZ515248A (en) 2004-01-30
EP1176956B1 (en) 2008-01-09
CA2373360A1 (en) 2000-11-16
WO2000067746A9 (en) 2002-08-29
EP1176956A1 (en) 2002-02-06
NO324421B1 (no) 2007-10-08
IL146311A0 (en) 2002-07-25
SK16082001A3 (sk) 2002-04-04
AU5267900A (en) 2000-11-21
HK1045805A1 (en) 2002-12-13
SI20744B (sl) 2009-08-31
ES2296625T3 (es) 2008-05-01
DK1176956T3 (da) 2008-05-26
EP1176956A4 (en) 2002-08-28
DE60037726T2 (de) 2009-03-05
RO122246B1 (ro) 2009-03-30
TR200201920T2 (tr) 2002-09-23
WO2000067746A1 (en) 2000-11-16
JP2002544161A (ja) 2002-12-24
IN2001KN01110A (https=) 2015-06-05
ZA200108774B (en) 2003-01-24

Similar Documents

Publication Publication Date Title
RU2263109C2 (ru) ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО
KR100851766B1 (ko) 인테그린이 이의 수용체에 결합하는 것을 억제하는 카복실산 유도체 및 이를 포함하는 약제학적 조성물
US6723711B2 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors
CA2328234C (en) Compounds that inhibit the binding of integrins to their receptors
KR100767199B1 (ko) 인테그린이 이의 수용체에 결합하는 것을 억제하는프로판산 유도체
CN101475526B (zh) 抑制整联蛋白与其受体结合的羧酸衍生物
AU782616B2 (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
CA2361285C (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors
HK1135376B (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
HK1045805B (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
KR20020009607A (ko) 인테그린이 이의 수용체에 결합하는 것을 억제하는카복실산 유도체
SI21098A1 (sl) Derivati propanojske kisline, ki inhibirajo vezavo integrinov na njihove receptorje

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160506